Fluorescein-labeled anti-human globulins were examined to determine the need for standardization of conjugates used in the fluorescent treponemal antibodyabsorption (FTA-ABS) test. Twenty-one of 33 conjugates submitted by commercial manufacturers to the Reagents Control Activity, Venereal Disease Research Laboratory, for evaluation in the FTA-ABS test were available for study. Conjugates, after evaluation in FTA-ABS performance tests, were examined by immunoelectrophoresis, by titration against immunoglobulins G and M (IgG, IgM) with FTA-ABS techniques, and by the biuret protein and fluorescein diacetate methods for determining fluorescein to protein (F/P) ratios. The conjugates were predominately anti-IgG globulin with anti-light-chain activity. Differences were noted in the ability of some conjugates to detect IgM antibody. The F/P ratios of those conjugates that could be determined varied from 2.6 to 17.8 j,g of fluorescein per mg of protein. The need to identify and standardize both the immunologic capabilities and the optimum F/P ratio for FTA-ABS test conjugates is presented.
The fluorescent treponemal antibody-absorption (FTA-ABS) test, as presently performed at the Venereal Disease Research Laboratory (VDRL), has progressed through several developmental stages (9) . During this period, most of the fluorescein-labeled anti-human globulins used in this test were purchased from commercial manufacturers after prior evaluation of their performance in the test procedure (15) .
With the interest in and development of methods for standardization of immunofluorescent reagents, the need for specifications of all fluorescent antibody reagents became apparent. To determine the immunochemical properties of conjugates considered acceptable for the FTA-ABS by current performance testing, and to establish areas requiring standardization, the scope of conjugate evaluation was expanded. Conjugates were evaluated to determine their immunoglobulin specificities and their fluorescein to protein (F/P) ratios. The information obtained through this study is reported.
MATERIALS AND METHODS
Fluorescein-labeled anti-human globulins for the FTA-ABS test were submitted by commercial manufacturers to the Reagents Control Activity, VDRL, for evaluation. Thirty-three conjugates, packaged as for sale, were tested in 1969 and 1970. Twenty-one of these conjugates were of sufficient quantity to be referred to the research area for further study.
FTA-ABS test. Acceptability for the FTA-ABS test was determined by titrations and test performance as described in the VDRL protocol for evaluation of reagents for FTA-ABS tests. The criteria of acceptability specified in the protocol are that the new conjugate should not stain a reference FTA-ABS antigen nonspecifically at three doubling dilutions below its working titer, and that in parallel tests with a reference conjugate it should give identical test results on controls and individual sera. The procedure for establishing the working titer for the conjugate is first to establish the highest dilution giving maximum (4+) fluorescence with a reactive control serum. The working titer is one doubling dilution below this endpoint.
Immunoelectrophoresis.
Immunoelectrophoretic studies were made according to established procedures (13) Antibody activity against a normal human pool
An-An-Anti-ti-tiIgG IgA 1IgM greater sensitivity of the immunofluorescent procedure for detecting antibody (10) . Also, it suggests either too much dilution of antibody before packaging or insufficient antibody development. Immunoelectrophoresis is widely used for the evaluation of labeled globulin, and antibody should be of sufficient concentration to be detected. Immunoelectrophoresis has also provided an excellent method for following antibody development and for determining efficiency of globulin fractionation.
Nonspecific staining between the antigen and labeled globulin is the main cause for unsatisfactory conjugates in the FVTA-ABS test. Earlier work had indicated that the presence of common or specific (Treponema cuniculi) treponemal antibody in animals used for production of antisera or cross-reactivity between the labeled antibody and the rabbit serum coating the antigen (or both) are possible causes of nonspecific staining (8) . Also, both the quantity (6) and the quality (1) of the fluorescein dye used in labeling has been demonstrated to affect nonspecific staining in labeled preparations. In this study, the unsatisfactory reagents generally had low specific titers and were The F/P ratio of those globulins in which it could be determined varied from 2.6 to 17.8 ,ug per mg. Most of these globulins contained contaminating protein from the animal host, and this must be considered when relating the F/P ratios to meaningful data (7) . The F/P ratios for the satisfactory reagents suggested that the low dyeto-protein ratios were preferable.
The data give direction for defining the immunochemical characteristics of the FTA-ABS test conjugates and show the value of extending conjugate characterizations to cover these parameters. The immunoglobulin specificity and the selected working dilution of anti-human globulin preparations in any test procedure should be based on the determination of the need to recognize IgG and IgM antibody. The limits to which conjugates with different immunoglobulin speci-VOL. 5, 1972 ficities can be interchanged in the FTA-ABS test without affecting test results should be critically reviewed.
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